Ruberg, F. L., & Maurer, M. S. (2024). Cardiac Amyloidosis Due to Transthyretin Protein. JAMA, 331(9), 778. https://doi.org/10.1001/jama.2024.0442

Maurer, M. S., Kale, P., Fontana, M., Berk, J. L., Grogan, M., Gustafsson, F., Hung, R. R., Gottlieb, R. L., Damy, T., González-Duarte, A., Sarswat, N., Sekijima, Y., Tahara, N., Taylor, M. S., Kubanek, M., Donal, E., Palecek, T., Tsujita, K., Tang, W. H. W., … Gillmore, J. D. (2023). Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis. New England Journal of Medicine, 389(17), 1553–1565. https://doi.org/10.1056/nejmoa2300757

Sperry, B. W., Hanna, M., Maurer, M. S., Nativi-Nicolau, J., Floden, L., Stewart, M., Wyrwich, K. W., Barsdorf, A. I., Kapadia, H., & Spertus, J. A. (2023). Association of Tafamidis With Health Status in Patients With ATTR Cardiac Amyloidosis. JAMA Cardiology, 8(3), 275. https://doi.org/10.1001/jamacardio.2022.5251

Brannagan, T. H., Berk, J. L., Gillmore, J. D., Maurer, M. S., Waddington‐Cruz, M., Fontana, M., Masri, A., Obici, L., Brambatti, M., Baker, B. F., Hannan, L. A., Buchele, G., Viney, N. J., Coelho, T., & Nativi‐Nicolau, J. (2022). Liver‐directed drugs for transthyretin‐mediated amyloidosis. Journal of the Peripheral Nervous System, 27(4), 228–237. Portico. https://doi.org/10.1111/jns.12519

Parcha, V., Malla, G., Irvin, M. R., Armstrong, N. D., Judd, S. E., Lange, L. A., Maurer, M. S., Levitan, E. B., Goyal, P., Arora, G., & Arora, P. (2022). Association of Transthyretin Val122Ile Variant With Incident Heart Failure Among Black Individuals. JAMA, 327(14), 1368. https://doi.org/10.1001/jama.2022.2896